Estimating the implicit value of statistical life based on public interventions implemented in the Netherlands

International Journal of Technology Assessment in Health Care

Volumn 24, Issue 4, 2008, Pages 495-501

  Goebbels, Adrienne F G ^a   Ament, André J H A ^a   Novák, Annoesjka ^b   Veraart, Christiaan P W M ^c   Severens, Johan L ^a,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Anovak Services   (Netherlands)

^c Roche Netherlands BV   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Economic evaluation; Investment analysis; Life saving interventions; Value of statistical life; Willingness to pay

Indexed keywords

COMMERCE; INVESTMENTS; RISK ASSESSMENT; STATISTICS;

ECONOMIC EVALUATION; INVESTMENT ANALYSIS; LIFE SAVING INTERVENTIONS; VALUE OF STATISTICAL LIFE; WILLINGNESS TO PAY;

STATISTICAL METHODS;

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; SIALIDASE INHIBITOR;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; INFLUENZA VACCINATION; MEDICAL LITERATURE; NETHERLANDS; PUBLIC HEALTH SERVICE; STATISTICAL ANALYSIS; VACCINATION;

HEALTH CARE RATIONING; HUMANS; NETHERLANDS; PUBLIC HEALTH PRACTICE; PUBLIC POLICY; VALUE OF LIFE;

EID: 53149106628     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462308080653     Document Type: Article

References (30)

1. Alban S. The 'precautionary principle' as a guide for future drug development. Eur J Clin Invest. 2005;35(Suppl 1):33-44.
2. Bellavance F, Georges D, Lebeau M. The value of a statistical life: A meta-analysis with a mixed effects regression model. Working paper 06-12. Montreal: Canada Research Chair in Risk Management; 2006.
3. Bos JM, Beutels P, Annemans L, Postma MJ. Valuing prevention trough economic evaluation: Some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics. 2004;22:1171-1179.
4. Brownson RC, Royer C, Ewing R, et al. Researchers and policymakers: Travellers in parallel universes. Am J Prev Med. 2006;30:167-172.
5. Card WI, Mooney GH. What is the monetary value of human life? BMJ. 1977;2:1627-1629.
6. Claxton K, Sculpher M, Cuyler A, et al. Discounting and cost-effectiveness in NICE-stepping back to sort out a confusion. Health Econ. 2006;15:1-4.
7. CVZ. Richtlijnen voor farmaco-economisch onderzoek. Diemen: CVZ; 2006.
8. CVZ. Farmacotherapeutisch Kompas. http://www.fk.cvz.nl. Accessed 22 May 2007.
9. CVZ. Medicijnkosten. http://www.medicijnkosten.nl. Accessed 28 June 2007.
10. De Blaeij A. The value of statistical life in road safety: Stated preference methodologies and empirical estimates for the Netherlands. Amsterdam: PhD Thesis, VU University; 2003.
11. De Blaeij A, Florax RJGM, Rietveld P, et al. The value of statistical life in road safety: A meta-analysis. Accid Anal Prev. 2003;35:973-986.
12. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
13. Evans MF, Smith VK. Do we really understand the age-VSL relationship? Resour Energy Econ. 2006;28:242-261.
14. Fuchs VR, Zeckhauser R. Valuing health: A "priceless" commodity. Am Econ Rev. 1987;77:263-268.
15. Genugten MLL, Heijnen MLA, Jager JC. Scenario analysis of the expected number of hospitalisations and deaths due to pandemic influenza in the Netherlands. Bilthoven: RIVM; 2002.
16. Johansson P, Kriström B. Introduction. Resour Energy Econ. 2006;28:193-198.
17. Langeveld PMM, Schoon CC. Kosten-batenanalyse van maatregelen voor vrachtauto's en bedrijven (report no.: R-2004-11). Leidschendam: SWOV; 2004.
18. Mathijssen J, Petersen A, Besseling P, et al. Omgaan met Onzekerheid in Beleid. Den Haag: CPB, MNP & RAND Europe.
19. Miller TR. Variations between countries in values of statistical life. J Transport Econ Pol. 2000;34:399-416.
20. Ministry of Health Welfare and Sports. Hoogervorst tekent contract levering antivirale middelen. Press report from September 9th 2005. The Hague: Ministry of Health Welfare and Sports.
21. NZA. Tarievenlijst Huisartsenzorg-Bijlage bij tariefbeschikking 5000-1900-07-1. Utrecht: NZA; 2006.
22. Postma MJ, Novak A, Scheijbeler HW, et al. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: Illustration for the Netherlands. Pharmacoeconomics. 2007;25:497-509.
23. Rabl A, Spadaro JV. Environmental impacts and costs of energy. Ann N Y Acad Sci. 2006;1076:516-526.
24. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: The ongoing debate. Value Health. 2004;7:397-401.
25. Ten Brinke WMBJ, Bannink BA. Risico's in bedijkte termen: een thematische evaluatie van het Nederlandse veiligheidsbeleid tegen overstromen (Report no. 500799002). Bilthoven: RIVM; 2004.
26. Van Der Baan F, Donk S, Jansen H, et al. The price of precaution: Measures to reduce the risk of contamination with vCJD via pharmaceutical products. Utrecht: University of Utrecht, Faculty of Geosciences; 2006.
27. Van Kampen LTB, Schoon CC. De veiligheid van vrachtauto's : een ongevals- en maatregelanalyse in opdracht van Transport en Logistiek Nederland. Leidschendam: SWOV; 1999.
28. Van Velden ME, Severens JL, Novak A. Economic evaluations of healthcare programmes and decision making: The influence of economic evaluations on different healthcare decision-making levels. Pharmacoeconomics. 2005;23:1075-1082.
29. Viscusi WK, Harrington JE, Vernon JM. Economics of regulation and antitrust. Cambridge: MIT Press; 2005.
30. Viscusi WK, Aldy JE. The value of a statistical life: A critical review of market estimates throughout the world. J Risk Uncertain. 2003;27:5-76.